Metagenomi (MGX) Competitors $2.89 +0.11 (+3.96%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.87 -0.02 (-0.69%) As of 10/24/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. MRNA, SLDB, DRUG, MBX, PRTC, AUTL, NGNE, EOLS, BNTC, and AMRNShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Solid Biosciences (SLDB), Bright Minds Biosciences (DRUG), MBX Biosciences (MBX), PureTech Health (PRTC), Autolus Therapeutics (AUTL), Neurogene (NGNE), Evolus (EOLS), Benitec Biopharma (BNTC), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Moderna Solid Biosciences Bright Minds Biosciences MBX Biosciences PureTech Health Autolus Therapeutics Neurogene Evolus Benitec Biopharma Amarin Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation. Is MGX or MRNA more profitable? Moderna has a net margin of -94.31% compared to Metagenomi's net margin of -257.99%. Moderna's return on equity of -25.96% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-257.99% -37.84% -27.15% Moderna -94.31%-25.96%-20.09% Does the media prefer MGX or MRNA? In the previous week, Moderna had 46 more articles in the media than Metagenomi. MarketBeat recorded 52 mentions for Moderna and 6 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.98 beat Moderna's score of -0.03 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 9 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 6 Negative mention(s) 6 Very Negative mention(s) Neutral Which has more volatility and risk, MGX or MRNA? Metagenomi has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Moderna has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Which has stronger valuation & earnings, MGX or MRNA? Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M2.07-$78.06M-$2.36-1.22Moderna$3.24B3.23-$3.56B-$7.53-3.55 Do insiders and institutionals hold more shares of MGX or MRNA? 75.3% of Moderna shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Comparatively, 10.9% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate MGX or MRNA? Metagenomi presently has a consensus target price of $10.00, suggesting a potential upside of 246.02%. Moderna has a consensus target price of $36.86, suggesting a potential upside of 37.84%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Moderna 5 Sell rating(s) 12 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.00 SummaryModerna beats Metagenomi on 8 of the 15 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$108.47M$2.63B$6.22B$10.81BDividend YieldN/A57.77%5.72%4.81%P/E Ratio-1.2227.9431.5030.91Price / Sales2.07786.96594.92133.93Price / CashN/A168.8137.2561.86Price / Book0.465.6512.056.61Net Income-$78.06M$33.06M$3.34B$277.10M7 Day Performance-5.25%3.16%1.93%2.57%1 Month Performance25.65%8.14%7.77%3.79%1 Year Performance44.50%-2.49%56.40%33.01% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.9799 of 5 stars$2.89+4.0%$10.00+246.0%+50.5%$108.47M$52.29M-1.22236News CoverageAnalyst UpgradeMRNAModerna4.1833 of 5 stars$27.24+4.7%$39.93+46.6%-49.4%$10.16B$3.24B-3.625,800Trending NewsAnalyst ForecastAnalyst RevisionSLDBSolid Biosciences2.9673 of 5 stars$6.15+4.6%$15.00+143.9%+0.5%$457.87M$8.09M-2.20100News CoverageAnalyst ForecastDRUGBright Minds Biosciences3.1828 of 5 stars$65.71+4.1%$81.00+23.3%+23.6%$444.76MN/A-70.66N/APositive NewsMBXMBX Biosciences3.5046 of 5 stars$14.23+7.6%$44.00+209.2%N/A$444.11MN/A-3.13N/APositive NewsAnalyst ForecastInsider TradePRTCPureTech Health0.3223 of 5 stars$18.29+1.6%N/A-15.0%$435.03M$4.83M0.00100Positive NewsAnalyst ForecastGap UpAUTLAutolus Therapeutics3.7682 of 5 stars$1.70+4.9%$9.12+436.5%-65.5%$431.15M$10.12M-2.02330Analyst ForecastNGNENeurogene1.8612 of 5 stars$32.16+10.8%$46.17+43.6%-38.0%$414.32MN/A-7.4690Analyst ForecastEOLSEvolus4.1201 of 5 stars$6.69+4.5%$21.25+217.6%-57.0%$413.99M$266.27M-6.83170BNTCBenitec Biopharma1.6657 of 5 stars$16.23+3.7%$24.80+52.8%+51.1%$410.82M$80K-11.0420News CoverageAnalyst ForecastAMRNAmarin0.9759 of 5 stars$20.25+3.1%$12.00-40.7%+71.5%$406.21M$228.61M-5.52360News CoverageUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Moderna Competitors Solid Biosciences Competitors Bright Minds Biosciences Competitors MBX Biosciences Competitors PureTech Health Competitors Autolus Therapeutics Competitors Neurogene Competitors Evolus Competitors Benitec Biopharma Competitors Amarin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
